Exelixis Outlines Growth Strategy as CABOMETYX Franchise Reaches $2.12B, Zanzalintinib Launch by 2026



Exelixis Outlines Growth Strategy as CABOMETYX Franchise Reaches $2.12B, Zanzalintinib Launch by 2026



Source link

  • Related Posts

    Rapid Micro Biosystems COO Wilson sells $17k of stock

    Rapid Micro Biosystems COO Wilson sells $17k of stock Source link

    Intact non-GAAP financial EPS of C$5.50

    Intact non-GAAP financial EPS of C$5.50 Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *